Biotech News

Alzamend Neuro to Present at the 2025 Military Health System Research Symposium

Alzamend Neuro (ALZN)Alzamend Neuro2025-07-28 12:00 ESTCompany update

ALZN (ALZN) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is alzn.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Open original release

Alzamend Neuro

Alzamend Neuro is a neuroscience company focused on Alzheimer's disease and other neuropsychiatric disorders. Its story is built around high-risk CNS development and novel treatment approaches.

Recent company news

ALZNAlzamend Neuro2026-04-07 12:00 EST

Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

ALZNAlzamend Neuro2026-03-26 12:00 EST

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

ALZNAlzamend Neuro2026-03-16 12:00 EST

Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

ALZNAlzamend Neuro2025-11-19 13:00 EST

Alzamend Neuro Announces Completion of Clinical Portion of Phase II Clinical Trial of AL001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital

ALZNAlzamend Neuro2025-07-28 12:00 EST